ZURA - Zura Bio Limited
Zura Bio Limited is a clinical-stage biotechnology company headquartered in San Diego, California, dedicated to pioneering new therapeutic solutions for immune system and inflammatory diseases. Its key product candidates include ZB-168, an anti-IL7Rα inhibitor engineered to address conditions influenced by the IL7 and TSLP biological pathways. The company is also advancing Torudokimab, a monoclonal antibody that neutralizes IL-33, which is currently in Phase 2 clinical development.
As of Jun 30, 2026: spot at $5.81, ATM IV 95.9%, max pain $5.00, net GEX $7.9K.
- Sector
- Healthcare
- Industry
- Biotechnology
- Market Cap
- $347.9M
- Beta
- 0.03
- 52-Week Range
- 1-7.44
- CEO
- Sandeep C. Kulkarni
- Employees
- 30
- IPO Date
- Mar 21, 2023
- Exchange
- NASDAQ
What ZURA Looks Like to Options Traders Today
IV rank of 20.7% is subdued relative to the 1-year history, conditions that typically favor premium-buying or long-volatility structures (debit spreads, calendar spreads, long straddles); positive net gamma exposure ($7.9K) means dealers hedge against trend, damping realized volatility and biasing price toward heavy-OI strikes; the 25-delta skew (-1.226) prices puts richer than calls, the typical equity downside-protection skew.
What This Page Covers
The ZURA overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure. Corporate data is on fundamentals, earnings, analyst ratings, and insider trading.
Frequently asked ZURA overview questions
- What is ZURA?
- ZURA is the ticker symbol for Zura Bio Limited, a listed security. Zura Bio Limited is a clinical-stage biotechnology company headquartered in San Diego, California, dedicated to pioneering new therapeutic solutions for immune system and inflammatory diseases. Its key product candidates include ZB-168, an anti-IL7Rα inhibitor engineered to address conditions influenced by the IL7 and TSLP biological pathways. Listed on NASDAQ. ZURA is the equity ticker shown on this page; equity options traders use the security for directional, volatility, and income strategies via the listed options chain.
- What does the ZURA options snapshot look like today?
- As of Jun 30, 2026, the ZURA options snapshot shows spot at $5.81, ATM IV 95.9%, IV rank 20.7%, max pain $5.00, net GEX $7.9K, expected move 27.49%. The full options chain, Greeks by strike and expiration, per-strike open-interest distribution, dealer gamma and delta exposure, and the volatility skew surface are linked from this overview page. Each per-metric route refreshes once per trading session and reflects the most recent close-of-business listed-options state.
- What are ZURA's key statistics?
- Zura Bio Limited (ZURA) carries a market capitalization of $347.9M, beta of 0.03 relative to the broader market, 52-week range of 1-7.44. Full income statement, balance sheet, cash flow, and TTM ratio history is on the per-ticker fundamentals page; daily price history and 52-week levels are accessible from the same view. These structural inputs frame how the options market prices implied volatility around earnings windows and capital events.
- What sector or industry does ZURA belong to?
- Zura Bio Limited operates in the Healthcare sector, in the Biotechnology industry. Sector classification affects how the ticker correlates with sector ETFs, how it reacts to macro factors like rate moves and commodity prices, and how its options pricing compares to sector peers. Compare ZURA's implied volatility and skew against sector benchmarks to gauge whether the options market is pricing single-name or systemic risk relative to the broader peer group.
- How current is the ZURA data on this page?
- The options snapshot above is dated Jun 30, 2026 and refreshes once per session, with all per-strike Greeks and exposure aggregates recomputed at the daily close. Company-profile fields (sector, industry, market cap, P/E, IPO date) refresh from the vendor feed nightly. Financials and earnings refresh as 10-K and 10-Q filings are parsed (typically within several business days of the actual report). FINRA microstructure data refreshes on the source's cadence (daily for short volume, bi-monthly for short interest, weekly for the OTC volume file, twice-monthly for SEC FTD).